about
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularizationLong-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trialCost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspectiveCoronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trialShort term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials.Duration of balloon inflation for optimal stent deployment: five seconds is not enough.Transradial approach for coronary angioplasty in the setting of acute myocardial infarction: a dual-center registry.Physicians, the medical device industry and the data; a healthy relationship?Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data.Cyclosporine before PCI in Patients with Acute Myocardial Infarction.Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial.Sex-related differences in clinical presentation and outcome of transcatheter aortic valve implantation for severe aortic stenosis.True percutaneous approach for transfemoral aortic valve implantation using the Prostar XL device: impact of learning curve on vascular complications.Risk profile and 3-year outcomes from the SYNTAX percutaneous coronary intervention and coronary artery bypass grafting nested registries.Analysis of stroke occurring in the SYNTAX trial comparing coronary artery bypass surgery and percutaneous coronary intervention in the treatment of complex coronary artery disease.Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.Stenting for small coronary vessels.Effect of gender after transcatheter aortic valve implantation: a meta-analysis.Revisiting Sex Equality With Transcatheter Aortic Valve Replacement Outcomes: A Collaborative, Patient-Level Meta-Analysis of 11,310 Patients.Percutaneous coronary intervention for bifurcation coronary disease.Cardiovascular magnetic resonance predictors of clinical outcome in patients with suspected acute myocarditis.Predictable and SuStainable Implementation of National Cardiovascular Registries (PASSION) infrastructure: A think tank report from Medical Device Epidemiological Network Initiative (MDEpiNet)Percutaneous aortic valve replacement: new hope for inoperable and high-risk patients.Why we should never return to bare metal stents?Comparison between the SAPIEN S3 and the SAPIEN XT transcatheter heart valves: A single-center experience.Are drug-eluting stents safe and effective in the long term?ACS and STEMI treatment: gender-related issues.First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial.Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS aCost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TFive-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial.Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II trial.Meta-Analysis of the Impact on Mortality of Noninfarct-Related Artery Coronary Chronic Total Occlusion in Patients Presenting With ST-Segment Elevation Myocardial Infarction.Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis.Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration.Influence of practice patterns on outcome among countries enrolled in the SYNTAX trial: 5-year results between percutaneous coronary intervention and coronary artery bypass grafting†.Quality of Life After Surgery or DES in Patients With 3-Vessel or Left Main Disease.Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting.The feasibility of transcatheter aortic valve implantation using the Edwards SAPIEN 3 for patients with severe bicuspid aortic stenosis.
P50
Q28202763-A335B77E-8508-4A8F-AB19-4DC6FA1F2507Q28251137-80D3309F-2CEA-4AD7-8334-863148AF542BQ28269638-622C3A5D-1287-42A0-A389-D49D070270E5Q28286188-A97AA69C-C69B-4EFF-B63B-AF546365F37EQ30241829-B29EFFE8-8600-4A96-B5D2-41138F33C3C2Q30409866-48723F2F-854C-45DA-AE9C-F5D85BDC23AEQ33183365-3000A064-CED8-4B3E-BE7E-D1AFA7AFE17BQ33503476-C2875C73-248E-4BB3-80FD-DAB31C673845Q34118922-466CF1A8-2A42-4696-86FC-A8CAEC5CCE01Q34491582-E5837374-3E1C-45B7-B7CD-F55FCA90B99DQ34555296-309D444D-D7A1-4EF5-B524-E3D4B0B58514Q34635605-E7FE8F40-3491-4D86-B090-5A504B15634CQ34636131-23B2433C-CB27-436E-AF1E-C4F745119128Q34639497-1445F63A-DAA5-48D8-B013-42ACE2C2DCCFQ34649683-B0F8F181-0D27-44EF-86B1-F24A6CEABDC8Q34948400-11BB9DEC-7060-4493-91EA-27EA210DFF96Q35168733-0F32FB83-487F-42B4-B9D8-0023A24A6FE3Q35551351-7B7B6ABF-3C53-45D7-BDEC-C6738DB9B1D1Q35694086-3BA384DF-CF73-46F7-9C27-2807920649CCQ35774808-4226E90A-1F18-484E-B820-6166DA17C29DQ36005589-B79E5408-2254-4993-8131-F34593E6B4CAQ36407121-7895AFB7-C4FC-42BA-A67C-A007AA392BA9Q36994875-35854145-2C4E-46FF-8CB3-6B00E29714AAQ37359514-B8061E6B-4211-410A-B1D7-5589046EA0DCQ37531961-13F8F715-C5C3-4451-AC69-0D0CA91E676BQ37827717-0416A1CA-FE51-49F0-AF34-52E2D4050B24Q38037246-4297C341-3A41-4C06-875A-5125A7016670Q38398602-D7C67D2F-1929-4DD8-A7BA-4EAAB43DF52AQ38408984-0EF17CA0-553C-47F8-99D4-77898579B1CEQ38413785-240F4182-F19A-43DB-B035-F9DBE8E33CCFQ38425971-3EA2BA56-6493-4B5C-92FA-F0A638DBE26FQ38432857-998D5781-D928-420F-BC0A-9577FB160239Q38484102-69EAF487-031A-4057-9155-D10C8E926F5DQ38525991-6927E430-E147-4BE6-934E-6C02EF568091Q38609667-CEB73142-D838-49B1-AAD0-66971A646488Q38704416-3D58F418-F5EE-4DBA-9FB6-E05B63DD86DEQ38777054-18381569-DBDE-4273-8786-358FE2DBF04FQ38828108-9E67836A-5BDF-4B27-B9A1-E7525BD4473FQ38828111-6BC7B398-9DD9-437F-B0DE-2C98CA25B09EQ38956685-4FF3C7DE-4DFD-4980-A572-EDD22ED972B4
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marie-Claude Morice
@ast
Marie-Claude Morice
@en
Marie-Claude Morice
@es
Marie-Claude Morice
@nl
type
label
Marie-Claude Morice
@ast
Marie-Claude Morice
@en
Marie-Claude Morice
@es
Marie-Claude Morice
@nl
prefLabel
Marie-Claude Morice
@ast
Marie-Claude Morice
@en
Marie-Claude Morice
@es
Marie-Claude Morice
@nl
P106
P31
P496
0000-0001-8308-6353